Renkonen R, Paavonen T, Nortamo P, Gahmberg C G
Department of Bacteriology, University of Helsinki, Finland.
Am J Pathol. 1992 Apr;140(4):763-7.
The authors have compared the reactivity of monoclonal antibodies (MAb) directed against endothelial adhesion molecules (ICAM-1, ICAM-2, VCAM-1, ELAM-1) in hyperplastic, nonmalignant, and malignant lymph nodes. The authors demonstrate that the reactivity with ICAM-1 MAb is stronger in the high endothelial venules (HEV) and other smaller vessels (SV) in lymphomas compared with hyperplastic lymph nodes. Similarly, the reactivity of an ICAM-2 MAb (6D5) was shown to be higher in malignant lymph nodes compared with nonmalignant ones. ICAM-2 MAb stained both the HEV and SV. VCAM-1 MAb reacted strongly with germinal centers and its endothelial reactivity was higher in the lymphoma nodes. ELAM-1 MAb stained only faintly some endothelial cells in malignant tissue. These data suggest that besides the known regulatable endothelial adhesion molecules ICAM-1 and VCAM-1, the expression of ICAM-2 can be modified.
作者比较了针对内皮细胞黏附分子(ICAM-1、ICAM-2、VCAM-1、ELAM-1)的单克隆抗体(MAb)在增生性、非恶性和恶性淋巴结中的反应性。作者证明,与增生性淋巴结相比,淋巴瘤的高内皮静脉(HEV)和其他较小血管(SV)中与ICAM-1 MAb的反应更强。同样,与非恶性淋巴结相比,ICAM-2 MAb(6D5)在恶性淋巴结中的反应性更高。ICAM-2 MAb对HEV和SV均有染色。VCAM-1 MAb与生发中心反应强烈,其在内皮细胞的反应性在淋巴瘤淋巴结中更高。ELAM-1 MAb仅微弱地染色恶性组织中的一些内皮细胞。这些数据表明,除了已知的可调节内皮细胞黏附分子ICAM-1和VCAM-1外,ICAM-2的表达也可被改变。